Phase I/II clinical trial for aGalCer resembling medicine,OCH in patients with Crohn s disease

Phase I/II clinical trial for aGalCer resembling medicine,OCH in patients with Crohn s disease - OCH NCNP1

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000023525

Enrollment

Registered

2016-08-08

Start date

2016-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn disease

Interventions

Cohort A (0.3mg daily) 4 cases Cohort B (3mg daily) 4 cases Cohort C (6mg daily) 4 cases

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) The patient who has been diagnosed as Crohn s disease 2) Patients whose CDAI is 150-450 others criteria can not uploaded due to the space.

Exclusion criteria

Exclusion criteria: 1) The patient who is suspected as other inflammatory bowel disease except Crohn s disease 2) Patient who will need bowel resection within 12 weeks after the entry of clinical trial. 3) Patient who is entering to another clinical trial or who receive medical treatment in any other clinical trial within 12 weeks prior to entry of the present clinical trial. others criteria can not uploaded due to the space.

Design outcomes

Primary

Measure	Time frame
Adverse event	—

Secondary

Measure	Time frame
Clinical efficacy Pharmacokinetics of OCH Pharmacodynamics of OCH	—

Countries

Japan

Contacts

Public ContactYoko Ito

Keio University Hospital Planning and Management Office Clinical and Translational Research Center

pmo@ccr.med.keio.ac.jp03-5315-4278

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026